FDA warns about use of certain glucose monitoring strips

Share this article:

The Food and Drug Administration Friday issued a public health notification regarding certain glucose monitoring strips.

It said that healthcare practitioners should not use GDH-PQQ (glucose dehydrogenase pyrroloquinoline quinine ) test strips on patients receiving therapeutic products containing non-glucose sugars. These sugars can falsely elevate glucose results, which may mask hypoglycemia or prompt excessive insulin administration, leading to a serious injury or death, the FDA said. Patients with serious medical conditions, including kidney failure and rheumatoid arthritis are most likely to use these therapies. Diabetics use glucose monitoring strips to test their blood sugar levels.

Other glucose test strips do not react harmfully with the non-glucose sugars, the FDA noted. The unaffected methods are glucose oxidase, glucose dehydrogenase nicotine adenine dinucleotide (GDH-NAD) or glucose dehydrogenase flavin adenine dinucleotide (GDH-FAD).

For more, click here.

 


Share this article:

More in News

Antipsychotics reduction goal is 25% by end of 2015, CMS and provider groups announce

Antipsychotics reduction goal is 25% by end of ...

Long-term care providers are being asked to reduce the use of antipsychotic medications among residents by 25% by the end of 2015, and 30% by the end of 2016. Providers ...

CDC issues new guidelines on pneumococcal vaccine, says LTC flu vaccination rates remain low

CDC issues new guidelines on pneumococcal vaccine, says ...

Long-term care workers continued to have low rates of flu vaccination last season, despite there being 92% vaccination coverage overall among physicians and nurses, the Centers for Disease Control and ...

AL operators accused of withholding $2M in unpaid overtime, minimum wages ...

Four California assisted living operators are facing eight felony charges related to wage theft, tax and insurance violations, according to local reports.